PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health

PhytoSERM 针对更年期潮热和持续大脑健康

• 批准号: 10707107
• 负责人: ROBERTA EILEEN BRINTON
• 金额: $ 119.93万
• 依托单位: NEUTHERAPEUTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10707107
• 关键词: 3 year old; Address; Age; Age Years; Aging; Alternative Health; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; American; Assessment tool; Biological Markers; Blood; Body Composition; Bone Density; Brain; Breast; Breast Cancer Risk Factor; Cell Proliferation; Clinical; Clinical Research; Clinical Trials; Cognition; Development; Disease; Double-Blind Method; Drug Kinetics; Elderly; Endocrine; Estrogen Receptor beta; Estrogen Therapy; Estrogens; Exhibits; Female; Formulation; Frequencies; Fright; Galvanic Skin Response; Genistein; Goals; Health; Hormones; Hot flushes; Inflammatory; Intervention; Life; Mammary Gland Parenchyma; Measures; Medical; Menopausal Symptom; Menopause; Menstruation; Metabolic; Monitor; National Institute on Aging; Neurologic; Neurosecretory Systems; Night Sweating; Participant; Perimenopause; Personal Satisfaction; Phase; Phenotype; Physiological; Phytoestrogens; Placebos; Plants; Postmenopause; Prevention strategy; Proliferating; Randomized; Research Support; Risk; Risk Reduction; Selective Estrogen Receptor Modulators; Severities; Sleep; Sleep disturbances; Symptoms; Technology; Therapeutic; Time; Tissues; Translating; Translations; Uterus; Woman; Women' s Health; Wrist; age related; aged; associated symptom; blood-based biomarker; brain health; clinical development; cognitive function; critical period; daidzein; data acquisition; digital; effective intervention; effective therapy; efficacy evaluation; equol; estrogenic; experience; hormone therapy; innovation; lifetime risk; lipidomics; malignant breast neoplasm; menopausal aging; menopausal hormone therapy; middle age; open label; oral supplementation; placebo group; pre-clinical; prevent; randomized placebo-controlled clinical trial; rational design; reproductive; treatment strategy; wearable device

PROJECT SUMMARY/ABSTRACT Women are at greater life-time risk for Alzheimer’s disease (AD). One potential factor contributing to greater life-time risk of AD is the midlife menopausal endocrine aging transition when multiple AD risk conditions can emerge and which are consistent with prodromal / preclinical features of the disease. While estrogen or hormone therapy administered when menopausal women are symptomatic could reduce risk of AD, the fear of breast cancer leads many women to forego this approach. An innovative alternative to estrogen therapy is to target estrogen action in brain while avoiding estrogen-associated proliferation in breast tissue. To achieve that goal, we propose Phase 2 clinical development of “PhytoSERM”, a selective estrogen receptor beta (ERß) modulator that promotes estrogenic action through ERß in brain while inhibitory in reproductive tissue. PhytoSERM is a rationally designed formulation of 3 phytoestrogens (each are Generally Recognized as Safe by the FDA). Our earlier NIA supported PhytoSERM Phase 1b/2a clinical trial determined that PhytoSERM was safe and well-tolerated, exhibited predictive pharmacokinetics in peri- and postmenopausal women and identified responder phenotype (https://clinicaltrials.gov/ct2/show/NCT01723917). Proposed herein is a Phase 2, double-blind, parallel-group, randomized, placebo-controlled clinical trial with an open-label extension to determine efficacy of PhytoSERM in symptomatic peri- and post-menopausal women. Primary objectives are to determine the efficacy of PhytoSERM to alleviate menopausal symptoms, mainly hot flashes. Secondary objectives are to evaluate the effect of PhytoSERM on: 1) cognitive function, 2) sleep disturbances, and 3) non-neurologic menopausal symptoms, including bone mineral density and body composition. Tertiary objectives are to determine impact of PhytoSERM on blood-based AD biomarkers. This Phase 2 PhytoSERM clinical trial addresses multiple strategic directions of the National Institutes on Aging’s 2020-2025: Aging Well in the 21st Century ref Specifically, Goal C-3 to: “Develop effective interventions to maintain health, well-being, and function and prevent or reduce the burden of age-related diseases” and “Conduct clinical studies / translation of new interventions to the clinical setting.” Goal D-4: Translate basic discovery into effective treatment and/or prevention strategies for AD/ADRD and” Goal F-4: Support research on women’s health.” PhytoSERM clinical trial also contributes to achieving the National Alzheimer’s Disease Project Act (NAPA) to effectively prevent and treat AD by 2025 Goal 1B. PhytoSERM addresses a critical unmet need in women’s health to reduce risk of Alzheimer’s in later life.

项目总结/摘要 女性一生中患阿尔茨海默病（AD）的风险更大。导致AD终身风险增加的一个潜在因素是中年绝经期内分泌衰老过渡，此时可能出现多种AD风险状况，并且与疾病的前驱/临床前特征一致。虽然当绝经期妇女有症状时给予雌激素或激素治疗可以降低AD的风险，但对乳腺癌的恐惧导致许多妇女放弃这种方法。雌激素治疗的一个创新替代方案是靶向脑中的雌激素作用，同时避免乳腺组织中雌激素相关的增殖。为了实现这一目标，我们提出了“PhytoSERM”的2期临床开发，这是一种选择性雌激素受体β（ER β）调节剂，通过ER β在大脑中促进雌激素作用，同时在生殖组织中抑制。PhytoSERM是一种合理设计的3种植物雌激素配方（每种都被FDA公认为安全）。我们早期的NIA支持的PhytoSERM 1b/2a期临床试验确定PhytoSERM是安全的，耐受性良好，在绝经期和绝经后妇女中表现出预测性药代动力学，并确定了应答表型（https：//clinicaltrials.gov/ct2/show/NCT01723917）。本文提出的是一项2期、双盲、平行组、随机化、安慰剂对照的临床试验，具有开放标签扩展，以确定PhytoSERM在有症状的绝经期和绝经后妇女中的功效。主要目的是确定PhytoSERM缓解更年期症状（主要是潮热）的疗效。次要目的是评估PhytoSERM对以下方面的影响：1）认知功能，2）睡眠障碍，和3）非神经系统更年期症状，包括骨矿物质密度和身体成分。第三个目标是确定PhytoSERM对血液AD生物标志物的影响。这项2期PhytoSERM临床试验解决了美国国立老龄研究所2020-2025年的多个战略方向：21世纪的老龄化，具体而言，目标C-3是：“开发有效的干预措施，以维持健康，福祉和功能，预防或减少与年龄相关的疾病的负担”和“进行临床研究/将新的干预措施转化为临床研究”。 设置”。目标D-4：将基本发现转化为AD/ADRD的有效治疗和/或预防战略以及”目标F-4：支持妇女健康研究”。PhytoSERM临床试验还有助于实现国家阿尔茨海默病项目法案（NAPA），以有效预防和治疗AD到2025年目标1B。PhytoSERM解决了女性健康中一个关键的未满足的需求，以减少老年痴呆症的风险。